Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine.
Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Kalikawe R, Datwani S, Burns L, Young L, Leung V, Ennis S, Brumme CJ, Montaner JSG, Dong W, Prystajecky N, Lowe CF, DeMarco ML, Holmes DT, Simons J, Niikura M, Romney MG, Brumme ZL, Brockman MA. Mwimanzi F, et al. Among authors: prystajecky n. Open Forum Infect Dis. 2023 Feb 9;10(3):ofad073. doi: 10.1093/ofid/ofad073. eCollection 2023 Mar. Open Forum Infect Dis. 2023. PMID: 36910697 Free PMC article.
Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada.
Skowronski DM, Setayeshgar S, Zou M, Prystajecky N, Tyson JR, Galanis E, Naus M, Patrick DM, Sbihi H, El Adam S, Henry B, Hoang LMN, Sadarangani M, Jassem AN, Krajden M. Skowronski DM, et al. Among authors: prystajecky n. Clin Infect Dis. 2022 Apr 9;74(7):1158-1165. doi: 10.1093/cid/ciab616. Clin Infect Dis. 2022. PMID: 34244723 Free PMC article.
Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada.
Skowronski DM, Setayeshgar S, Zou M, Prystajecky N, Tyson JR, Sbihi H, Fjell CD, Galanis E, Naus M, Patrick DM, El Adam S, Ahmed MA, Kim S, Henry B, Hoang LMN, Sadarangani M, Jassem AN, Krajden M. Skowronski DM, et al. Among authors: prystajecky n. J Infect Dis. 2022 Aug 12;226(1):485-496. doi: 10.1093/infdis/jiac023. J Infect Dis. 2022. PMID: 35084500 Free PMC article.
Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada.
Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R, Brousseau N, Deceuninck G, Galanis E, Fjell CD, Sbihi H, Fortin E, Barkati S, Sauvageau C, Naus M, Patrick DM, Henry B, Hoang LMN, De Wals P, Garenc C, Carignan A, Drolet M, Jassem AN, Sadarangani M, Brisson M, Krajden M, De Serres G. Skowronski DM, et al. Among authors: prystajecky n. Clin Infect Dis. 2022 Nov 30;75(11):1980-1992. doi: 10.1093/cid/ciac290. Clin Infect Dis. 2022. PMID: 35438175 Free PMC article.
Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose.
Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Datwani S, Omondi FH, Burns L, Young L, Leung V, Agafitei O, Ennis S, Dong W, Basra S, Lim LY, Ng K, Pantophlet R, Brumme CJ, Montaner JSG, Prystajecky N, Lowe CF, DeMarco ML, Holmes DT, Simons J, Niikura M, Romney MG, Brumme ZL, Brockman MA. Mwimanzi F, et al. Among authors: prystajecky n. J Infect Dis. 2022 Sep 21;226(6):983-994. doi: 10.1093/infdis/jiac199. J Infect Dis. 2022. PMID: 35543278 Free PMC article.
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses.
Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Speckmaier S, Moran-Garcia N, Datwani S, Duncan MC, Agafitei O, Ennis S, Young L, Ali H, Ganase B, Omondi FH, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes DT, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Pantophlet R, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. Lapointe HR, et al. Among authors: prystajecky n. J Infect Dis. 2023 Apr 12;227(7):838-849. doi: 10.1093/infdis/jiac229. J Infect Dis. 2023. PMID: 35668700 Free PMC article.
Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination.
Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Kalikawe R, Datwani S, Waterworth R, Umviligihozo G, Ennis S, Young L, Dong W, Kirkby D, Burns L, Leung V, Holmes DT, DeMarco ML, Simons J, Matic N, Montaner JSG, Brumme CJ, Prystajecky N, Niikura M, Lowe CF, Romney MG, Brockman MA, Brumme ZL. Lapointe HR, et al. Among authors: prystajecky n. Front Immunol. 2022 Sep 6;13:947021. doi: 10.3389/fimmu.2022.947021. eCollection 2022. Front Immunol. 2022. PMID: 36148225 Free PMC article.
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy.
Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Speckmaier S, Barad E, Moran-Garcia N, Datwani S, Duncan MC, Kalikawe R, Ennis S, Young L, Ganase B, Omondi FH, Umviligihozo G, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. Lapointe HR, et al. Among authors: prystajecky n. AIDS. 2023 Apr 1;37(5):709-721. doi: 10.1097/QAD.0000000000003469. Epub 2022 Dec 22. AIDS. 2023. PMID: 36545783 Free PMC article.
Adaptability of single-nucleotide polymorphism-polymerase chain reaction (SNP-PCR) for subtyping SARS-CoV-2 and a new SNP-PCR for XBB, XBB.1.5, and B.Q.1/B.Q.1.1.
Ritchie G, Young M, Prystajecky N, Romney MG, Lowe CF, Matic N. Ritchie G, et al. Among authors: prystajecky n. Clin Microbiol Infect. 2023 Oct;29(10):1339-1341. doi: 10.1016/j.cmi.2023.06.014. Epub 2023 Jun 15. Clin Microbiol Infect. 2023. PMID: 37330140 Free PMC article. No abstract available.
Rapid Increase in SARS-CoV-2 P.1 Lineage Leading to Codominance with B.1.1.7 Lineage, British Columbia, Canada, January-April 2021.
Hogan CA, Jassem AN, Sbihi H, Joffres Y, Tyson JR, Noftall K, Taylor M, Lee T, Fjell C, Wilmer A, Galbraith J, Romney MG, Henry B, Krajden M, Galanis E, Prystajecky N, Hoang LMN. Hogan CA, et al. Among authors: prystajecky n. Emerg Infect Dis. 2021 Nov;27(11):2802-2809. doi: 10.3201/eid2711.211190. Epub 2021 Aug 13. Emerg Infect Dis. 2021. PMID: 34388358 Free PMC article.
77 results